Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
ZEC faces panic selling and a one-sided decline, market maker Auros Global suffers more than $8.5 million in long position losses

ZEC faces panic selling and a one-sided decline, market maker Auros Global suffers more than $8.5 million in long position losses

BlockBeatsBlockBeats2026/06/05 07:35
Show original

BlockBeats reported on June 5 that, according to Hyperinsight monitoring, possibly affected by the ongoing discussions around the feasibility of “infinite minting”, ZEC experienced panic-driven sell-offs in the afternoon, resulting in a one-sided decline. Hyperliquid well-known market maker Auros Global was forced to take on a large long position during the price drop, now holding $10.5 million in long positions, with unrealized losses once expanding to $8.5 million (-450%).


As of press time, the total holdings at the Auros Global market making address reached $46.2 million, providing liquidity for 99 tokens. Recently, this address has significantly reduced the range of tokens it makes markets for, and the total holdings have also decreased.


Address: 0x023a3d058020fb76cca98f01b3c48c8938a22355

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage